Perez, EA and Baehner, FL and Butler, SM and Thompson, EA and Dueck, AC and Jamshidian, F and Cherbavaz, D and Yoshizawa, C and Shak, S and Kaufman, PA and Davidson, NE and Gralow, J and Asmann, YW and Ballman, KV
(2015)
The relationship between quantitative human epidermal growth factor receptor 2 gene expression by the 21-gene reverse transcriptase polymerase chain reaction assay and adjuvant trastuzumab benefit in Alliance N9831.
Breast Cancer Research, 17 (1).
ISSN 1465-5411
Abstract
Introduction: The N9831 trial demonstrated the efficacy of adjuvant trastuzumab for patients with human epidermal growth factor receptor 2 (HER2) locally positive tumors by protein or gene analysis. We used the 21-gene assay to examine the association of quantitative HER2 messenger RNA (mRNA) gene expression and benefit from trastuzumab. Methods: N9831 tested the addition of trastuzumab to chemotherapy in stage I-III HER2-positive breast cancer. For two of the arms of the trial, doxorubicin and cyclophosphamide followed by paclitaxel (AC-T) and doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab concurrent chemotherapy-trastuzumab (AC-TH), recurrence score (RS) and HER2 mRNA expression were determined by the 21-gene assay (Oncotype DX®) (negative <10.7, equivocal 10.7 to <11.5, and positive ≥11.5 log<inf>2</inf> expression units). Cox regression was used to assess the association of HER2 expression with trastuzumab benefit in preventing distant recurrence. Results: Median follow-up was 7.4years. Of 1,940 total patients, 901 had consent and sufficient tissue. HER2 by reverse transcriptase polymerase chain reaction (RT-PCR) was negative in 130 (14%), equivocal in 85 (9%), and positive in 686 (76%) patients. Concordance between HER2 assessments was 95% for RT-PCR versus central immunohistochemistry (IHC) (>10% positive cells = positive), 91% for RT-PCR versus central fluorescence in situ hybridization (FISH) (≥2.0 = positive) and 94% for central IHC versus central FISH. In the primary analysis, the association of HER2 expression by 21-gene assay with trastuzumab benefit was marginally nonsignificant (nonlinear p = 0.057). In hormone receptor-positive patients (local IHC) the association was significant (p = 0.002). The association was nonlinear with the greatest estimated benefit at lower and higher HER2 expression levels. Conclusions: Concordance among HER2 assessments by central IHC, FISH, and RT-PCR were similar and high. Association of HER2 mRNA expression with trastuzumab benefit as measured by time to distant recurrence was nonsignificant. A consistent benefit of trastuzumab irrespective of mHER2 levels was observed in patients with either IHC-positive or FISH-positive tumors. Trend for benefit was observed also for the small groups of patients with negative results by any or all of the central assays. Trial registration: Clinicaltrials.gov NCT00005970. Registered 5 July 2000.
Share
| Citation/Export: |
|
| Social Networking: |
|
Details
| Item Type: |
Article
|
| Status: |
Published |
| Creators/Authors: |
| Creators | Email | Pitt Username | ORCID  |
|---|
| Perez, EA | | | | | Baehner, FL | | | | | Butler, SM | | | | | Thompson, EA | | | | | Dueck, AC | | | | | Jamshidian, F | | | | | Cherbavaz, D | | | | | Yoshizawa, C | | | | | Shak, S | | | | | Kaufman, PA | | | | | Davidson, NE | ned23@pitt.edu | NED23 | | | Gralow, J | | | | | Asmann, YW | | | | | Ballman, KV | | | |
|
| Centers: |
Other Centers, Institutes, Offices, or Units > Pittsburgh Cancer Institute |
| Date: |
1 October 2015 |
| Date Type: |
Publication |
| Journal or Publication Title: |
Breast Cancer Research |
| Volume: |
17 |
| Number: |
1 |
| DOI or Unique Handle: |
10.1186/s13058-015-0643-7 |
| Schools and Programs: |
School of Medicine > Medicine |
| Refereed: |
Yes |
| ISSN: |
1465-5411 |
| Date Deposited: |
05 Aug 2016 17:29 |
| Last Modified: |
30 Mar 2021 15:55 |
| URI: |
http://d-scholarship.pitt.edu/id/eprint/29139 |
Metrics
Monthly Views for the past 3 years
Plum Analytics
Altmetric.com
Actions (login required)
 |
View Item |
![[img]](http://d-scholarship.pitt.edu/style/images/fileicons/text_plain.png)
![[feed]](/images/feed-icon-32x32.png){kind=icon}